[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

(708) 202-8387

Email address

douglas.lammie@va.gov

Condition

Diabetic Kidney Disease

Treatment type

Interventional

Investigational product

Pentoxifylline

Phase

Phase 4

Sponsor

VA Office of Research and Development

ClinicalTrials.gov identifier

NCT03625648

Study number

2008

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

Pentoxifylline (PTX) is a medication that has been on the market since 1984 for use in disease in the blood vessels of the legs. There is some preliminary information that it may protect the kidneys from damage due to diabetes and other diseases. "Pentoxifylline in Diabetic Kidney Disease" is a study to bee conducted in 40 VA hospitals across the nation to determine definitively whether or not PTX can prevent worsening of kidney disease and delay death in patients with diabetic kidney disease.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Type-2 diabetes
  2. Chronic Kidney Disease, stage 3 or 4 (eGFR 15-60 mL/min/1.73 m2) at the time of randomization and on one or more occasions 3 months or more prior to randomization
  3. Participants need to be in one of the following categories at the time of randomization and on one or more occasions 3 months or more prior to randomization:
  4. eGFR 15 to less than 30 mL/min/1.73 m2, or
  5. eGFR 30 to less than 45 mL/min/1.73 m2 with UACR > 30 mg/g*, or
  6. eGFR 45 to less than 60 mL/min/1.73 m2 with UACR > 300 mg/g**
  7. *For screening purposes only, UPCR > 150 mg/g acceptable.
  8. **For screening purposes only, UPCR > 500 mg/g acceptable.
Exclusion criteria

  1. Type 1 diabetes
  2. Known non-diabetic kidney disease
  3. Severe comorbid conditions (expected to reduce life expectancy to less than 1 year, as determined by LSI)
  4. Previous organ or bone marrow transplant
  5. Pregnancy, breast feeding or females of child-bearing potential who are unwilling to use a reliable form of contraception
  6. Presence of recent (within 3 months) cerebral hemorrhage
  7. Currently using oral PTX
  8. Hypersensitivity to PTX or any of the components of the formulation
  9. Current use of ketorolac (contraindicated with PTX )
  10. Current use of riociguat (contraindicated with PTX)
  11. Unable to provide informed consent

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site